中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
10期
651-654
,共4页
转移性乳腺癌%手术%局部切除
轉移性乳腺癌%手術%跼部切除
전이성유선암%수술%국부절제
metastatic breast cancer%surgery%local excision
目的：对转移性乳腺癌原发病灶是否行手术切除目前并未形成共识，本研究是通过分析转移性乳腺癌患者的临床资料，评价本组资料手术和非手术治疗方法的优劣。方法：收集2005年1月至2012年12月收治的120例原发性乳腺癌同时伴有远处转移患者的临床资料，将其分为手术组和非手术组，分析两组总体生存率和局部病灶进展情况，并进行统计学分析。结果：120例患者均获得随访，随访的中位时间为52（10～92）个月。手术组共55例，其中30例为术后围手术期内发现远处转移，非手术组65例。两组患者的肿瘤局部分期、淋巴结分期、肿瘤转移的部位差异均无统计学意义。与非手术组患者相比，手术组总体生存时间明显延长（49个月vs.33个月，P=0.016），有症状的局部病情进展比例明显降低（14.5%vs.46.2%，P<0.001）。结论：研究结果显示，对于转移性乳腺癌患者，切除原发病灶可有助于提高总体生存时间，延缓病情进展。但此结论仍需要多中心的临床研究结果证实。
目的：對轉移性乳腺癌原髮病竈是否行手術切除目前併未形成共識，本研究是通過分析轉移性乳腺癌患者的臨床資料，評價本組資料手術和非手術治療方法的優劣。方法：收集2005年1月至2012年12月收治的120例原髮性乳腺癌同時伴有遠處轉移患者的臨床資料，將其分為手術組和非手術組，分析兩組總體生存率和跼部病竈進展情況，併進行統計學分析。結果：120例患者均穫得隨訪，隨訪的中位時間為52（10～92）箇月。手術組共55例，其中30例為術後圍手術期內髮現遠處轉移，非手術組65例。兩組患者的腫瘤跼部分期、淋巴結分期、腫瘤轉移的部位差異均無統計學意義。與非手術組患者相比，手術組總體生存時間明顯延長（49箇月vs.33箇月，P=0.016），有癥狀的跼部病情進展比例明顯降低（14.5%vs.46.2%，P<0.001）。結論：研究結果顯示，對于轉移性乳腺癌患者，切除原髮病竈可有助于提高總體生存時間，延緩病情進展。但此結論仍需要多中心的臨床研究結果證實。
목적：대전이성유선암원발병조시부행수술절제목전병미형성공식，본연구시통과분석전이성유선암환자적림상자료，평개본조자료수술화비수술치료방법적우렬。방법：수집2005년1월지2012년12월수치적120례원발성유선암동시반유원처전이환자적림상자료，장기분위수술조화비수술조，분석량조총체생존솔화국부병조진전정황，병진행통계학분석。결과：120례환자균획득수방，수방적중위시간위52（10～92）개월。수술조공55례，기중30례위술후위수술기내발현원처전이，비수술조65례。량조환자적종류국부분기、림파결분기、종류전이적부위차이균무통계학의의。여비수술조환자상비，수술조총체생존시간명현연장（49개월vs.33개월，P=0.016），유증상적국부병정진전비례명현강저（14.5%vs.46.2%，P<0.001）。결론：연구결과현시，대우전이성유선암환자，절제원발병조가유조우제고총체생존시간，연완병정진전。단차결론잉수요다중심적림상연구결과증실。
Objective:Until recently, no consensus has been reached about the treatment of primary tumor in patients with meta-static breast cancer, and whether or not to excise it has not yet reached agreement. This study aimed to evaluate the value of surgical and nonsurgical treatment of primary tumor by analyzing the clinical data of patients with metastatic breast cancer. Methods:This re-view includes the data of 120 metastatic breast cancer patients. Their clinical data in Xiangyang Central Hospital (Hubei province) from January 2005 to December 2012 were collected. All cases were divided into surgical and nonsurgical groups, and the overall survival and symptomatic local progression rates were analyzed. Results:The 120 patients had a median follow-up of 52 months (range=10-92 months). A total of 55 cases were in the surgical group, 30 of whom had surgery before the metastatic diagnosis, and 65 cases were in the nonsurgical group. No significant differences were observed regarding the tumor classification, lymph-node classification, and meta-static site of the tumor in the two groups. Patients in the surgical group experienced longer overall survival (49 months vs. 33 months, P=0.016) and lower rates of symptomatic local progression (14.5%vs. 46.2%, P<0.001). Conclusion:This study demonstrated that the overall survival and symptomatic local control in the surgical group were better than those in the nonsurgical group. However, this hy-pothesis remains to be proved by multicenter clinical trials.
